^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET-targeted antibody-drug conjugate

    Related drugs:
    14h
    SKB571-II-02: A Phase II Study of SKB571 in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=295, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | N=190 --> 295
    Enrollment change
    2d
    Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | Trial completion date: Sep 2028 --> Dec 2027 | Trial primary completion date: Sep 2028 --> Dec 2027
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    telisotuzumab adizutecan (ABBV-400)
    2d
    EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov)
    P1, N=403, Recruiting, AstraZeneca | Trial completion date: Oct 2027 --> Aug 2028 | Trial primary completion date: Oct 2027 --> Aug 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR wild-type
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • 5-fluorouracil • leucovorin calcium • tilatamig samrotecan (AZD9592)
    8d
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection (clinicaltrials.gov)
    P1/2, N=465, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    12d
    Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. (PubMed, J Clin Oncol)
    Temab-A at 2.4 mg/kg once every 3 weeks has a tolerable and manageable safety profile, with promising antitumor activity.
    P1 data • Journal • First-in-human
    |
    BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    BRAF wild-type
    |
    telisotuzumab adizutecan (ABBV-400) • telisotuzumab (h224G11)
    14d
    An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer. (PubMed, Expert Opin Biol Ther)
    While accelerated approval underscores its therapeutic promise, long-term positioning will depend on confirmatory trials, refinement of biomarker testing, and optimization of patient selection. If validated, this strategy may redefine later-line treatment expectations by aligning cytotoxic payload delivery with biologically enriched disease subsets.
    Review • Journal • IO Companion diagnostic • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR wild-type • MET overexpression
    |
    Emrelis (telisotuzumab vedotin-tllv)
    20d
    A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. (PubMed, Cell Rep Med)
    In preclinical studies, B6ADC exhibits potent cytotoxicity in vitro across various TROP2/c-Met-expressing cancer cell lines and superior tumor inhibition in vivo compared with single-target ADC combination, including the clinically approved TROP2 ADC sacituzumab govitecan and c-Met ADC Teliso-V, as well as their combination. Notably, B6ADC eradicates giant tumors with a single dose at a low concentration of 2.2 mg/kg. We present a nanobody-based BsADC that simultaneously targets TROP2 and c-Met, with broad-spectrum antitumor activity, and improves selectivity for tumors with dual-positive or weakly positive antigen expression, offering a promising strategy for treating pancreatic cancer and other TROP2/c-Met-expressing malignancies.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    MET expression
    |
    Trodelvy (sacituzumab govitecan-hziy) • Emrelis (telisotuzumab vedotin-tllv)
    20d
    A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=140, Recruiting, Chong Kun Dang Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET overexpression • MET expression
    23d
    Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • MET overexpression • EGFR exon 20 mutation
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody • VENTANA® MET (SP44) RxDx Assay
    |
    Tagrisso (osimertinib) • Emrelis (telisotuzumab vedotin-tllv)
    28d
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=854, Recruiting, AbbVie | Trial completion date: Dec 2031 --> Nov 2036
    Trial completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • telisotuzumab adizutecan (ABBV-400)
    29d
    A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=23, Terminated, Genmab | Trial completion date: Jun 2028 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: May 2028 --> Mar 2026; Genmab has decided to terminate the GEN1286 program due to an unfavorable benefit-risk profile not supporting further development.
    Trial completion date • Trial termination • Trial primary completion date
    30d
    A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=700, Not yet recruiting, AbbVie
    New P3 trial
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)